Cancer-associated Thrombosis: EVE & API-CAT - Prof. Robert McBane and Prof. Isabelle Mahé скачать в хорошем качестве

Cancer-associated Thrombosis: EVE & API-CAT - Prof. Robert McBane and Prof. Isabelle Mahé

Prof. Robert McBane (Rochester, MN, USA) and Prof. Isabelle Mahé (Paris, France) discuss long-term anticoagulation after cancer-associated Thrombosis (CAT), focussing upon the EVE study and the ongoing APICAT study. Professor Dr. Robert McBane is a Vascular Medicine consultant at Mayo Clinic, Rochester, Minnesota. He has conducted numerous randomized trials in cancer-associated thrombosis, including the ADAM VTE and EVE trials. Professor Dr. Isabelle Mahé is Chef de Service at Hôpital Louis Mourier, Service de Médecine Interne at Université Paris Cité and president of the scientific counsel of the French INNOVTE network. She is Principle Investigator of the APICAT trial, which will become the largest randomized clinical trial ever performed in CAT. The interview was recorded on October 31th, 2023. Moderators: Prof. Dr. Florian Langer (Hamburg, Germany) and Prof. Dr. Gunnar Heine (Frankfurt, Germany). Articles discussed: Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial. McBane RD 2nd, Loprinzi CL, Ashrani A, Lenz CJ, Houghton D, Zemla T, Le-Rademacher JG, Wysokinski WE. Eur J Haematol. 2020 doi: 10.1111/ejh.13338 Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. J Thromb Haemost. 2020 doi: 10.1111/jth.14662 Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. Mahé I, Agnelli G, Ay C, Bamias A, Becattini C, Carrier M, Chapelle C, Cohen AT, Girard P, Huisman MV, Klok FA, López-Núñez JJ, Maraveyas A, Mayeur D, Mir O, Monreal M, Righini M, Samama CM, Syrigos K, Szmit S, Torbicki A, Verhamme P, Vicaut E, Wang TF, Meyer G, Laporte S. Thromb Haemost. 2022 doi: 10.1055/a-1647-9896. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Becattini C, Bauersachs R, Maraziti G, Bertoletti L, Cohen A, Connors JM, Manfellotto D, Sanchez A, Brenner B, Agnelli G. Haematologica. 2022 doi: 10.3324/haematol.2021.279072 Edoxaban for 12 Months Versus 3 Months in Cancer Patients With Isolated Distal Deep Vein Thrombosis (ONCO DVT study): An Open-label, Multicenter, Randomized Clinical Trial. Yamashita Y, Morimoto T, Muraoka N, Oyakawa T, Umetsu M, Akamatsu D, Nishimoto Y, Sato Y, Takada T, Jujo K, Minami Y, Ogihara Y, Dohi K, Fujita M, Nishikawa T, Ikeda N, Hashimoto G, Otsui K, Mori K, Sueta D, Tsubata Y, Shoji M, Shikama A, Hosoi Y, Tanabe Y, Chatani R, Tsukahara K, Nakanishi N, Kim K, Ikeda S, Mo M, Yoshikawa Y, Kimura T; ONCO DVT Study Investigators. Circulation. 2023 doi: 10.1161/CIRCULATIONAHA.123.066360 Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m). Marshall A, Levine M, Hill C, Hale D, Thirlwall J, Wilkie V, French K, Kakkar A, Lokare A, Maraveyas A, Chapman O, Arif A, Petrou S, Maredza M, Hobbs R, Dunn JA, Young AM. J Thromb Haemost. 2020 doi: 10.1111/jth.14752 Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, Trinkaus M, Tomiak A, Lee AYY, Gross PL, Lazo-Langner A, El-Maraghi R, Goss G, Le Gal G, Stewart D, Ramsay T, Rodger M, Witham D, Wells PS; AVERT Investigators. N Engl J Med. 2019 doi: 10.1056/NEJMoa1814468 Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review. Bikdeli B, Zahedi Tajrishi F, Sadeghipour P, Talasaz AH, Fanikos J, Lippi G, Siegal DM, Eikelboom JW, Monreal M, Jimenez D, Connors JM, Ageno W, Barnes GD, Piazza G, Angiolillo DJ, Parikh SA, Kirtane AJ, Lopes RD, Bhatt DL, Weitz JI, Mehran R, Krumholz HM, Goldhaber SZ, Lip GYH. JAMA Cardiol. 2022 doi: 10.1001/jamacardio.2022.1292 Apixaban for extended treatment of venous thromboembolism. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; AMPLIFY-EXT Investigators. N Engl J Med. 2013 doi: 10.1056/NEJMoa1207541 Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M; Caravaggio Investigators. N Engl J Med. 2020 doi: 10.1056/NEJMoa1915103 Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. Giustozzi M et al. J Thromb Haemost. 2021 doi: 10.1111/jth.15461